Revenue (Annual)

Revenue: The sum of all revenue fields included for a company's operating activities.

Edwards Lifesciences Corporation (EW) had Revenue of $5.44B for the most recently reported fiscal year, ending 2024-12-31.

Quarterly Annual

Figures for fiscal year ending 2024-12-31

Income Statement Financials
Revenue	$5.44B
Net Income	$4.17B
Cost of Goods Sold	$1.12B
Gross Profit	$4.32B
Operating Expenses	$4.06B
Operating Income	$1.38B
Non-Operating Income/Expense	$169.40M
Pre-Tax Income	$1.55B
Normalized Pre-Tax Income	$1.55B
Income after Taxes	$1.40B
Income from Continuous Operations	$1.40B
Consolidated Net Income/Loss	$4.17B
Normalized Income after Taxes	$1.40B
EBIT	$1.38B
EBITDA	$1.53B
Weighted-Average Shares Outstanding (Basic)	597.70M
Weighted-Average Shares Outstanding (Diluted)	599.30M
Earnings per Share (EPS) (Basic)	$6.98
Earnings per Share (EPS) (Diluted)	$6.97
Balance Sheet Financials
Current Assets	$6.29B
Property, Plant, and Equipment	$1.69B
Long-Term Assets	$6.77B
Total Assets	$13.06B
Current Liabilities	$1.51B
Long-Term Debt	$597.70M
Long-Term Liabilities	$1.49B
Total Liabilities	$2.99B
Common Equity	$10.06B
Tangible Shareholders Equity	$7.11B
Shareholders Equity	$10.06B
Common Shares Outstanding	588.60M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$542.30M
Cash Flow from Investing Activities	$2.31B
Cash Flow from Financial Activities	$-983.00M
Beginning Cash	$1.15B
End Cash	$3.06B
Increase/Decrease in Cash	$1.91B
Stock-Based Compensation	$162.30M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	4.18
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.06
Debt to Equity Ratio	0.06
Gross Margin	79.46%
Operating Margin	25.35%
EBIT Margin	25.35%
EBITDA Margin	28.20%
Pre-Tax Profit Margin	28.46%
Profit Margin	76.75%
Free Cash Flow	$289.90M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.42
Inventory Turnover	1.03
Receiveable Turnover	7.48
Days Sales in Receivables	48.81
Return on Equity	13.87%
Return on Tangible Equity	19.64%
Return on Assets	10.69%
Return on Investments	13.10%
Book Value Per Share	$17.10
Free Cash Flow per Share	$0.48
Operating Cash Flow per Share	$0.90

Data from Zacks Investment Research, Inc.